Aurinia announced the submission of its Investigational New Drug application to the U.S. FDA for AUR200, a potential next generation therapy for B-cell mediated autoimmune diseases. Upon receiving FDA clearance to proceed with proposed research, Aurinia plans to initiate a Phase 1 study in the first half of 2024 to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic properties of AUR200 in healthy volunteers.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AUPH:
- Aurinia Pharmaceuticals put volume heavy and directionally bearish
- Aurinia Pharmaceuticals call volume above normal and directionally bullish
- Aurinia strength may be related to Gilead suspicion, says Gordon Haskett
- Aurinia Pharmaceuticals partner Otsuka files NDA in Japan for Lupkynis
- Aurinia Pharmaceuticals narrows FY23 net product revenue to $155M-$160M